The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found. Researchers agree it is important to minimize delays in making treatments for diseases such as cancer available to patients, but they say their findings point to a need for greater transparency around how drugs receive approval. For many drugs that have been tested in multiple clinical trials, pharmaceutical companies are only required to share the results from two trials, leaving questions about why they chose those two for submission and what happened in the other trials, study co-author Veronica Irvin said.

https://www.miragenews.com/osu-studies-fda-fast-tracks-drug-approvals-1071721/

#miragenews